Article

MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits.

Department of Cardiovascular Surgery, Tohuko University Graduate School of Medicine, Sendai, Japan.
Journal of Thoracic and Cardiovascular Surgery (Impact Factor: 3.53). 12/2003; 126(5):1461-6. DOI: 10.1016/S0022
Source: PubMed

ABSTRACT The mechanism of spinal cord injury is believed to be related to the vulnerability of spinal motor neuron cells against ischemia. We tested whether MCI-186, which is useful for treating ischemic damage in the brain, can protect against ischemic spinal cord damage.
After induction of ischemia, MCI-186 or vehicle was injected intravenously. Cell damage was analyzed by observing the function of the lower limbs and by counting the number of motor neurons. To investigate the mechanism by which MCI-186 prevents ischemic spinal cord damage, we observed the immunoreactivity of Cu/Zn superoxide dismutase, neuronal nitric oxide synthase, and endothelial nitric oxide synthase.
MCI-186 eased the functional deficits and increased the number of motor neurons after ischemia. The induction of neuronal nitric oxide synthase was significantly reduced by the treatment with MCI-186. Furthermore, the increase in the induction of endothelial nitric oxide synthase and Cu/Zn superoxide dismutase was more pronounced.
These results indicate that MCI-186 may protect motor neurons from ischemic injury by reducing neuronal nitric oxide synthase and increasing endothelial nitric oxide synthase. MCI-186 may be a strong candidate for use as a therapeutic agent in the treatment of ischemic spinal cord injury.

0 Bookmarks
 · 
61 Views
  • Neurologia Medico-chirurgica - NEUROL MED-CHIR. 01/2008; 48(12):539-545.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Los resultados de estudios previos han sugerido que la edavarona intravenosa en dosis altas (3-10 mg/kg) protege frente a la lesión isquémica de la médula espinal. El presente estudio examinó si la inyección directa del fármaco en dosis bajas en el segmento clampado de aorta previene dicha lesión. Mediante clampaje aórtico por debajo de la arteria renal y por encima de la bifurcación aórtica, se indujo isquemia de la médula espinal en conejos durante 15 min en condiciones de normotermia. En los grupos A y B se inyectaron 3 y 1 mg/kg de edaravona, respectivamente, en el segmento clampado de la aorta inmediatamente después del clampaje. En el grupo C, se inyectó suero salino. La función neurológica se evaluó a las 8, 24 y 48 h y a los 7 días después de la reperfusión con los criterios de Tarlov. La médula espinal se examinó histológicamente a los 7 días con tinción de hematoxilina-eosina y con la técnica de tinción TUNEL (in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling). Durante todo el período, en los grupos A y B, la puntuación de Tarlov permaneció en un grado 4, mientras que, a los 7 días, disminuyó hasta un grado 0 o 1 en el grupo C, siendo significativamente más alta en los dos primeros grupos. Comparado con el grupo C, el número de neuronas motoras intactas fue significativamente mayor en los grupos A y B con menos neuronas motoras necróticas. Entre los grupos A y B, no se identificó una diferencia significativa con respecto a la protección de la médula espinal. En ningún grupo se observaron neuronas TUNEL positivas, indicativo de la ausencia de la apoptosis. La inyección de edavarona intraaórtica en dosis bajas previene la lesión neuronal inmediata al reducir la lesión de las neuronas en un estadio inicial, al igual que la diferida a los 7 días.
    Anales de Cirugía Vascular. 01/2009; 23(1).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oxidative stress is implicated as an important factor in the development of Alzheimer's disease (AD). In the present study, we have investigated the effects of edaravone (9mg/kg, 3-Methyl-1-phenyl-2-pyrazolin-5-one), a free radical scavenger, in a streptozotocin (STZ-3mg/kg) induced rat model of sporadic AD (sAD). Treatment with edaravone significantly improved STZ-induced cognitive damage as evaluated in Morris water maze and step-down tests and markedly restored changes in malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) adducts, hydroxyl radical (·OH), hydrogen peroxide (H2O2), total superoxide dismutase (T-SOD), reduced glutathione (GSH), glutathione peroxidase (GPx) and protein carbonyl (PC) levels. In addition, histomorphological observations confirmed the protective effect of edaravone on neuronal degeneration. Moreover, hyperphosphorylation of tau resulting from intracerebroventricular streptozotocin (ICV-STZ) injection was decreased by the administration of edaravone. These results provide experimental evidence demonstrating preventive effects of edaravone on cognitive dysfunction, oxidative stress and hyperphosphorylation of tau in ICV-STZ rats. Since edaravone has been used for treatment of patients with stroke, it represents a safe and established therapeutic intervention that has the potential for a novel application in the treatment of age-related neurodegenerative disorders associated with cognitive decline, such as AD.
    NeuroToxicology 08/2013; · 2.65 Impact Factor

Full-text (2 Sources)

Download
18 Downloads
Available from
May 17, 2014